Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

39.64 +0.87 (+2.24%)
Official Closing Price Updated: 7:00 PM EDT, Aug 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,525,597
Open 38.90
Bid (Size) 39.00 (1)
Ask (Size) 40.03 (1)
Prev. Close 38.77
Today's Range 38.72 - 39.74
52wk Range 33.67 - 45.92
Shares Outstanding 5,385,189,617
Dividend Yield 3.64%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
From GSK plc
Via Business Wire
British Pharma Giant GSK's Blockbuster Shingles And Respiratory Syncytial Virus Vaccine Q2 Sales Miss Expectations, Cuts Annual Vaccine Revenue Guidance
GSK reported Q2 sales of $9.95 billion, beating estimates of $9.66 billion. Specialty Medicine sales rose 20%, driven by strong HIV, Respiratory/Immunology, and Oncology performance. Core EPS of $1.10... 
Via Benzinga
Topics Earnings
Exposures Financial

Performance

YTD
+5.68%
+5.68%
1 Month
+3.74%
+3.74%
3 Month
-8.56%
-8.56%
6 Month
-2.44%
-2.44%
1 Year
+14.47%
+14.47%

More News

Read More
GSK Beats Second-Quarter Views, Raises Outlook; But Shares Fall On Shingrix Miss
Via Investor's Business Daily
GSK Stock Earnings: GSK Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
Via Benzinga
Topics Economy
Exposures Interest Rates
Is GSK a Top-Value Stock Right Now?
Via The Motley Fool
Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests
Via Benzinga
Wall Street Remains On Track For AMD-Led Rebound Ahead Of Fed Decision, Meta Earnings: Analyst Says 'The Bull Tends To Remain' Despite Near-Time Volatility
Via Benzinga
Topics Economy
Exposures Interest Rates
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
Via Benzinga
3 Stocks Under $10 With the Potential for Massive Gains
Via InvestorPlace
Top Research Reports For Apple, Lowe's & Shopify
Via Talk Markets
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
Via Benzinga
Exposures COVID-19
3 Top Cancer Treatment Stocks to Buy Now
Via InvestorPlace
Positive News is Driving This Cancer Drug Maker’s Stock Higher
Via MarketBeat
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
Via InvestorPlace
Topics Economy
Exposures Economy
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
From GSK plc
Via Business Wire
3 Dirt-Cheap Drug Developers With Blockbuster Potential
Via InvestorPlace
Health Officials Keep Close Eye On Bird Flu As It Infects Cows For The First Time
Via Benzinga
The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024
Via InvestorPlace
Pfizer's RSV Vaccine Abrysvo Clears Concerns Over Preterm Birth Risk, Safety For Pregnant Women, New Study Shows
Via Benzinga
United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win
Via Benzinga
Topics ETFs
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Via InvestorPlace
CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.